Collaborative Counseling Considerations for Pharmacogenomic Tests
- 7 August 2017
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 37 (9), 990-999
- https://doi.org/10.1002/phar.1980
Abstract
Increased use of pharmacogenomic (PGx) testing in the clinical setting has revealed a number of challenges to providing this service. PGx is an important component of precision medicine that brings together the fields of genetics and clinical pharmacology. A model that incorporates a multidisciplinary approach to implementation and information delivery may be the most beneficial to patients and providers. In this review, translational considerations in the provision of PGx testing and counseling services are described. Specifically, we report on the selection of PGx tests, the provision of patient education and counseling, and examples of PGx service delivery models that incorporate counseling by pharmacists and genetic counselors. Examples of ancillary risks associated with PGx testing, testing of children, and familial implications of testing are reviewed. Through multispecialty partnerships, including genetic counselors and pharmacists, implementation obstacles to PGx testing can be overcome to provide quality precision medicine to patients.Keywords
This publication has 60 references indexed in Scilit:
- The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomics–PharmacogenomicsClinical Pharmacology & Therapeutics, 2013
- Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithmsEuropean Journal of Clinical Pharmacology, 2013
- Insurance Coverage Policies for Personalized MedicineJournal of Personalized Medicine, 2012
- Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT ProjectClinical Pharmacology & Therapeutics, 2012
- Public Perspectives About Pharmacogenetic Testing and Managing Ancillary FindingsGenetic Testing and Molecular Biomarkers, 2012
- Professional Perspectives About Pharmacogenetic Testing and Managing Ancillary FindingsGenetic Testing and Molecular Biomarkers, 2012
- Motivators for participation in a whole-genome sequencing study: implications for translational genomics researchEuropean Journal of Human Genetics, 2011
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research NetworkClinical Pharmacology & Therapeutics, 2011
- Adverse drug events in the outpatient setting: an 11‐year national analysisPharmacoepidemiology and Drug Safety, 2010
- Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestryProceedings of the National Academy of Sciences of the United States of America, 2009